Viberzi® (eluxadoline) is a prescription medicine used to treat irritable bowel syndrome with diarrhea (IBS-D).  Viberzi® works by decreasing bowel contractions which leads to less diarrhea.  

Risk of Pancreatitis

On March 15, 2017, the US Food and Drug Administration (FDA) issued a warning that Viberzi® should not be used in patients who do not have a gallbladder due to an increased risk of developing serious pancreatitis that could result in hospitalization or death.  This increased risk may be experienced with a single dose. Subsequently, in April 2017 the Prescribing Information was changed to contraindicate Viberzi® use in patients without a gallbladder.  

Viberzi® was first approved in May 2015.  At the time of the FDA warning less than two years later, the FDA had already received at least 120 reports of serious pancreatitis or death associated with Viberzi®.  In 76 of these cases, the patient was hospitalized and 2 of those patients died.  The agency found that cases of serious pancreatitis often occurred after only a few doses.  The FDA also determined that patients without a gallbladder were at an increased risk of pancreatitis.  

How We Can Help

Our firm is dedicated to serving those who are wrongfully injured, and to the fair and just resolution of their claims.  The lawyers at Blackridge LLC have extensive experience litigating thousands of cases involving injuries from pharmaceuticals and medical devices.  We represent individuals throughout the United States who have suffered serious injuries and death as a result of poorly designed drugs and devices. Our experienced lawyers zealously pursue each and every case to ensure our clients receive their rightful compensation.

Related Links

Free Confidential Case Evaluation

If you or a loved one experienced pancreatitis while taking Viberzi®, please complete the no obligation confidential case evaluation below.  An attorney will contact you within the next business day.